Composition and methods for inducing myeloid suppressive cells and use thereof

Patent metadata

Field	Value
Publication number	US-11851677-B2
Application number	US-201816622237-A
Country	US
Kind code	B2
Filing date	Jun 13, 2018
Priority date	Jun 13, 2017
Publication date	Dec 26, 2023
Grant date	Dec 26, 2023

Abstract

Compositions and methods for manufacturing induced immune regulatory cells comprising induced myeloid suppressive cells including MDSCs (myeloid-derived suppressor cells), dendritic cells, macrophages, and subpopulations thereof are provided. Also provided are methods and compositions for further modifying and modulating the induced immune regulatory cells to achieve enhanced therapeutic potential in treating autoimmune disorders, hematological malignancies, solid tumors, viral infections, neurodegenerative disorders, inflammatory conditions, or GvHD.

First claim

What is claimed is:

1. An in vitro method of generating a population of induced immune regulatory cells, comprising:
(i) obtaining induced definitive hemogenic endothelium cells (iHE); and
(ii) directing differentiation of iHE with a medium composition comprising a ROCK inhibitor, GMCSF, and MCSF;
thereby generating a population of induced immune regulatory cells comprising induced myeloid suppressive cells, wherein the induced myeloid suppressive cells are CD45 + and CD33 + ;
and wherein the cell population has enhanced therapeutic potential.

2. The method of claim 1 , wherein:
a) the medium composition further comprises (1) one or more growth factors and cytokines selected from the group consisting of ILlb, IL3, IL6, IL4, IL10, IL13, TGFβ, bFGF, VEGF, SCF, and FLT3L, and optionally, (2) one or both of an AhR antagonist and a prostaglandin pathway agonist;
b) the medium composition is feeder-free, and/or serum-free;
c) the population of induced myeloid suppressive cells comprise induced myeloid-derived suppressor cells (iMDSs);
d) the population of induced immune regulatory cells comprises a subpopulation of: (i) monocytic MDSCs (M-MDSCs); (ii) CD45 + CD33 + CD14 + cells; (iii) CD45 + CD33 + PDL1 + cells; (iv) granulocytic MDSCs (G-MDSCs); (v) CD45 + CD14 − CD15 + CD11b + cells; (vi) CD45 + CD206 + cells; or (vii) CD45 + CD11c + CD14 − HLADR high cells;
e) the population of induced immune regulatory cells comprises:
(1) more than 90% of iMDSCs, wherein the iMDSCs comprise monocytic MDSCs;
(2) more than 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of monocytic MDSCs, and/or CD45 + CD33 + PDL1 + cells; wherein the monocytic MDSCs comprise CD45 + CD33 + CD14 + cells; and/or
(3) more than 20%, 30%, 40% or 50% of granulocytic MDSCs, wherein the granulocytic MDSCs comprise CD45 + CD11b + CD14 − CD15 + cells; and/or
(4) more than 20%, 30%, 40% or 50% of macrophages; wherein the macrophages comprise CD45 + CD206 + cells; and/or
(5) more than 20%, 30%, 40% or 50% of dendritic cells; wherein the dendritic cells comprise CD45 + CD11c + CD14 − HLADR high cells;

f) the population of induced immune regulatory cells comprises iMDSCs and is essentially free of granulocytes, erythrocytes, and/or lymphoid cells;
g) the induced myeloid suppressive cells comprised in the population of induced immune regulatory cells comprise one or more genetic imprints obtained from genetically engineering the induced myeloid suppressive cells;
h) the induced myeloid suppressive cells comprised in the population of induced immune regulatory cells comprise one or more genetic imprints retained from iHE comprising the same genetic imprint(s);
i) the iHE cells are derived from induced pluripotent stem cells (iPSC), iPSC derived mesodermal cells, or iPSC derived mesodermal cells with definitive hemogenic endothelium potential; and optionally the iPSC comprises one or more genetic imprints retainable by its derived cells;
j) the ROCK inhibitor is thiazovivin or Y27632; or
k) the enhanced therapeutic potential comprises (1) increased number or ratio of induced MDSCs in the induced immune regulatory cell population; (2) improved potency in suppressing T cell proliferation and effector function; or (3) ability in attenuating GvHD,
as compared to myeloid suppressive cells comprised in PBMC (peripheral blood mononuclear cell).

3. The method of claim 2 , wherein:
a) the AhR antagonist comprises StemRegenin1 (SR1);
b) the one or more genetic imprints of iPSC are obtained by a method comprising: (i) obtaining a source specific immune cell that is donor-, disease-, or treatment response-specific, wherein the immune cell presents retainable therapeutic attributes; and (ii) reprogramming the source specific immune cell to iPSC; or by a method comprising genomic editing during or after reprogramming a non-pluripotent cell to iPSC, wherein the genetic imprint comprises one or more genetically modified modalities introduced through genomic insertion, deletion or substitution in the genome of the iPSC;
c) the method further comprises genomic editing of the induced myeloid suppressive cells through genomic insertion, deletion or substitution in the genome of the induced myeloid suppressive cells to introduce one or more genetically modified modalities to the cells; or
d) the method further comprises modulating the induced myeloid suppressive cells of by contacting one or more modulating agents to enhance therapeutic potential of the cells.

4. The method of claim 3 , wherein the genetically modified modalities comprise:
a) one or more of: safety switch proteins, targeting modalities, receptors, signaling molecules, transcription factors, pharmaceutically active proteins and peptides, drug target candidates; or proteins promoting engraftment, trafficking, homing, viability, self-renewal, persistence, immune response regulation and modulation, and/or survival of the induced myeloid suppressive cells or one or more of the subpopulations thereof,
b) introduced or increased expression of a chimeric receptor, a homing receptor, an anti-inflammatory molecule, an immune checkpoint protein, a

cytokine/chemokine decoy receptor, a growth factor, an altered proinflammatory cytokine receptor, a CAR, or a surface triggering receptor for coupling with bi- or multi-specific or universal engagers; and optionally, wherein the introduced or increased expression is driven by a promoter regulated by inflammatory signaling; and/or
c) reduced or silenced expression of a co-stimulatory gene.

5. The method of claim 4 , wherein:
a) the genetically modified modalities comprise (i) deletion or reduced expression of B2M, TAP1, TAP2, Tapasin, NLRC5, RFXANK, CITTA, RFX5, RFXAP, or any of the HLA genes in the chromosome 6p21 region; or (ii) introduced or increased expression of IDO1, PDL1, CTLA4, Arg1, IL35, IL10, HO-1, CrmB, Y136, HGFL, GMCSF, TGFβ, HLA-E, HLA-G, CAR, or surface triggering receptors for bi- or multi-specific engagers;
b) the chimeric receptor comprises (i) an extracellular domain comprising an antigen specific binding sequence, an immunoglobulin, or a pro-inflammatory cytokine receptor; and (ii) an intracellular domain for anti-inflammatory signaling comprising at least one of IL10R, IL35R, and AhR;
c) the homing receptor or adhesion molecule comprises CXCR4, CCR2, CCR5, CCR6, CXCR3, CCR7, CD62L, or VLA4;
d) the promoter (i) is a promoter driven by inflammatory signaling comprising TLR or IFNγR signaling; (ii) is an inducible promoter; and/or (iii) is triggered only after homing of the iMDSCs;
e) the altered pro-inflammatory cytokine receptor (i) sequesters pro-inflammatory cytokines comprising IL2R, IL6R, or IFNγR; (ii) is membrane bound; or (iii) is in a soluble form; or
f) the bi- or multi-specific engager is specific to one or more tumor-specific antigen on the surface of a tumor cell.

6. The method of claim 3 , wherein the therapeutic attributes of the source specific immune cell comprise one or more of (i) antigen targeting receptor expression; (ii) HLA presentation or lack thereof, (iii) resistance to tumor microenvironment; (iv) induction of bystander immune cells and immune modulations; (iv) improved on-target specificity with reduced off-tumor effect; (v) resistance to treatment such as chemotherapy; and (vi) improved homing, persistence, and cytotoxicity.

7. The method of claim 2 , wherein deriving iHE cells from induced pluripotent stem cells (iPSC) further comprises differentiating iPSCs to mesodermal cells; differentiating iPSC derived mesodermal cells to mesodermal cells with definitive hemogenic endothelium potential; and differentiating iPSC derived mesodermal cells with definitive hemogenic endothelium potential to iHE.

8. The method of claim 7 , wherei

Assignees

• Fate Therapeutics Inc

Inventors

• Parone Philippe A
• Tacke Robert S
• Valamehr Bahram
• Shoemaker Daniel
• Hosking Martin
• Guerrettaz Lisa

Classifications

• A61K40/418

  Antigens related to induction of tolerance to non-self · CPC title

• A61K40/22

  Immunosuppressive or immunotolerising · CPC title

• A61K40/10

  characterised by the cell type used · CPC title

• A61K2239/31

  characterized by the route of administration · CPC title

• A61K2239/38

  characterised by the dose, timing or administration schedule · CPC title